Can a simple pill stop hepatitis b from waking up during cancer treatment?
NCT ID NCT05453435
First seen May 27, 2026 · Last updated Jun 09, 2026 · Updated 1 time
Summary
This study looks at whether the antiviral drug entecavir can prevent hepatitis B from reactivating in people with a type of blood cancer (CD20-positive B-cell lymphoma) who have had hepatitis B in the past but cleared it. About 84 participants will take entecavir during and for 6 months after their cancer treatment. The goal is to see if this approach reduces the chance of the virus becoming active again.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESOLVED HEPATITIS B are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University
Guangzhou, State..., 510060, China
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.